Pharmalink’s $15M Series C Financing To Progress Assets And Strategy
This article was originally published in The Pink Sheet Daily
Privately held Pharmalink of Sweden will use a $15 million Series C funding for pivotal studies in its lead cancer and renal disease drugs, and to shop for new in-licensing or M&A opportunities in the Nordic region.
You may also be interested in...
Calliditas is aiming to raise new funding in an IPO and listing on Nasdaq Sweden to support late-stage clinical development and commercialization of its Berger's disease candidate, and studies in additional indications.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.